IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2331 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal


Year : 2022  |  Volume : 54  |  Issue : 5  |  Page : 373-376

Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma

1 Department of Pharmacy, Hospital Universitario Puerto Real, Cadiz; Department of Pharmacology, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain
2 Department of Pharmacy, Hospital General Nuestra Señora del Prado, Toledo, Spain
3 Department of Hematology, Hospital General Nuestra Señora del Prado, Toledo, Spain

Correspondence Address:
Manuel David Gil-Sierra
Calle Playa de Bolonia No 10, Cádiz-11406
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijp.ijp_563_21

Rights and Permissions

Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall survival by short follow-up of patients with poor prognoses. Cases with long follow-ups could provide additional information about BLMF. This case reports a patient with MM treated with BLMF who had received nine previous lines of therapy with a follow-up of 11 months. No complete response was obtained. However, no disease progression was observed and the patient was still alive at the end of this work. BLMF showed manageable adverse effects. Our patient presented advanced disease, good functional status at the beginning of BLMF treatment, and elevated levels of lactate dehydrogenase during BLMF therapy. The influence of these last two factors was not evaluated in clinical trials. This relationship should be assessed more deeply in future studies.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow